Drug Combination Details
| General Information of the Combination (ID: C69480) | |||||
|---|---|---|---|---|---|
| Name | Silymarin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combined applications of doxorubicin and silymarin caused higher apoptosis and necrosis of cells in 24 h than that of single agent applications. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Genotoxic and cytotoxic effects of doxorubicin and silymarin on human hepatocellular carcinoma cells. Hum Exp Toxicol. 2014 Dec;33(12):1269-76. | |||
